• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Surges 2%; Best Buy Posts Upbeat Earnings

    11/22/22 12:40:32 PM ET
    $API
    $BBY
    $BTU
    $COSM
    Computer Software: Prepackaged Software
    Technology
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Get the next $API alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 250 points on Tuesday.

    The Dow traded up 0.83% to 33,981.56 while the NASDAQ rose 0.37% to 11,065.13. The S&P 500 also rose, gaining, 0.69% to 3,977.00.

    Also check this: Disney Brings Back Bob Iger As CEO, Here's A Look At Recent Price Target Cuts By The Most Accurate Analysts


    Leading and Lagging Sectors


    Energy shares rose by 2.3% on Tuesday. Leading the sector was strength from Peabody Energy Corporation (NYSE:BTU) and Ranger Oil Corporation (NASDAQ:ROCC).


    In trading on Tuesday, real estate slipped by 0.1%.


    Top Headline

     

    Best Buy Co (NYSE:BBY) reported better-than-expected Q3 results.

    The company reported third-quarter revenue of $10.59 billion, which beat average analyst estimates of $10.31 billion. Best Buy reported third-quarter earnings of $1.38 per share, which beat average estimates of $1.03 per share.

     

    Equities Trading UP

     

    • Palisade Bio, Inc. (NASDAQ:PALI) shares shot up 101% to $4.46 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery.
    • Shares of Cosmos Holdings Inc. (NASDAQ:COSM) got a boost, shooting 67% to $0.2933 after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.
    • ObsEva SA (NASDAQ:OBSV) shares were also up, gaining 27% to $0.2106 after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million.

     

    Equities Trading DOWN

    • MacroGenics, Inc. (NASDAQ:MGNX) shares tumbled 20% to $5.09 after Cowen & Co. downgraded the stock from Outperform to Market Perform.
    • Shares of Agora, Inc. (NASDAQ:API) were down 21% to $2.64 after the company posted downbeat Q3 results and issued weak FY22 sales forecast.
    • Eqonex Limited (NASDAQ:EQOS) was down, falling 28% to $0.1506 after dipping around 24% on Monday.


    Also check out: Nasdaq Drops Over 100 Points, But Market Volatility Decreases


    Commodities

    In commodity news, oil traded up 2% to $81.66 while gold traded up 0.1% at $1,741.40.


    Silver traded up 0.9% to $21.055 on Tuesday while copper rose 1.7% to $3.6310.


    Euro zone


    European shares were higher today. The eurozone’s STOXX 600 gained 0.81%, London’s FTSE 100 rose 1.05% while Spain’s IBEX 35 Index rose 1.75%. The German DAX gained 0.43%, French CAC 40 rose 0.47% and Italy’s FTSE MIB Index gained 1.09%.


    The current account surplus in the Eurozone narrowed sharply to EUR 3.8 billion in September from EUR 33.1 billion in the year-ago month. Italy recorded a current account deficit of EUR 2.018 billion in September versus a year-ago surplus of EUR 4.967 billion.

     

    Asia Pacific Markets


    Asian markets closed mostly lower on Monday, with the Japan’s Nikkei gaining 0.16% and Hong Kong’s Hang Seng Index falling 1.87%. China’s Shanghai Composite Index fell 0.39%.

     

    Economics


    The Richmond Fed Manufacturing Activity Index rose to -9 in November from -10 in the previous month.

     

    Check out this: Fear & Greed Index Remains In 'Greed' Zone Ahead Of Earnings


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 100,251,350 cases with around 1,102,910 deaths. India confirmed a total of at least 44,670,780 cases and 530,590 deaths, while France reported over 37,378,170 COVID-19 cases with 158,330 deaths. In total, there were at least 643,612,630 cases of COVID-19 worldwide with more than 6,628,050 deaths.

    Get the next $API alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $API
    $BBY
    $BTU
    $COSM

    CompanyDatePrice TargetRatingAnalyst
    Best Buy Co. Inc.
    $BBY
    2/2/2026$76.00Overweight → Neutral
    Analyst
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Best Buy Co. Inc.
    $BBY
    11/26/2025$90.00 → $95.00Outperform
    Telsey Advisory Group
    MacroGenics Inc.
    $MGNX
    9/17/2025$3.00Overweight
    Barclays
    Peabody Energy Corporation
    $BTU
    7/15/2025$14.00Neutral
    UBS
    Best Buy Co. Inc.
    $BBY
    7/14/2025$75.00Overweight → Neutral
    Piper Sandler
    Best Buy Co. Inc.
    $BBY
    5/23/2025$100.00 → $90.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $API
    $BBY
    $BTU
    $COSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Best Buy downgraded by Analyst with a new price target

    Analyst downgraded Best Buy from Overweight to Neutral and set a new price target of $76.00

    2/2/26 6:48:04 AM ET
    $BBY
    Consumer Electronics/Video Chains
    Consumer Discretionary

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $API
    $BBY
    $BTU
    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agora, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 2, 2026

    SANTA CLARA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ:API), a pioneer and leader in conversational AI and real-time engagement technology, will release its financial results for the fourth quarter and fiscal year ended December 31, 2025 after the close of U.S. markets on March 2, 2026. Agora, Inc. will host a conference call to discuss the financial results at 5 p.m. Pacific Time / 8 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 4Q 2025 Financial Results The call will be available at https://edge.media-server.com/mmc/p/9jcg52bqInvestors who want to hear the call should log on at least 15 minutes prior to t

    2/13/26 7:00:00 AM ET
    $API
    Computer Software: Prepackaged Software
    Technology

    KITCHENAID INTRODUCES ITS 2026 COLOUR OF THE YEAR: SPEARMINT

    Featuring a sand texture finish, this mint-green hue encourages calm and revitalizing energy amidst the chaos. TORONTO, Feb. 12, 2026 /CNW/ - Today, KitchenAid unveils its 2026 Colour of the Year: Spearmint. Spearmint is a light, uplifting minty-green hue with a tactile, sandy finish that provides a calming, yet revitalizing energy that brightens the world for a step into the fresh side. This year's colour also introduces a new textural finish to the KitchenAid brand Colour of the Year portfolio, Sand. "Research shows that amid global uncertainty, consumers are seeking renewal

    2/12/26 8:01:00 AM ET
    $BBY
    $WHR
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Consumer Electronics/Appliances

    Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies

    CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company's disciplined, opportunistic, and flexible approach to capital deployment. The Company's digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pillar of the program, the addition of Bitcoin represents a strategic evolution intended to broaden exposure across established digital assets. Cosmos Health is also selectively evaluati

    2/11/26 12:10:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $API
    $BBY
    $BTU
    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, CFO Finley John David converted options into 13,333 shares and sold $6,818 worth of shares (3,896 units at $1.75), increasing direct ownership by 53% to 27,353 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:07:40 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $API
    $BBY
    $BTU
    $COSM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Peabody Energy Corporation

    SCHEDULE 13G/A - PEABODY ENERGY CORP (0001064728) (Subject)

    2/13/26 4:10:03 PM ET
    $BTU
    Coal Mining
    Energy

    Amendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.

    SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/13/26 8:50:59 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Peabody Energy Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - PEABODY ENERGY CORP (0001064728) (Filer)

    2/5/26 7:47:26 AM ET
    $BTU
    Coal Mining
    Energy

    $API
    $BBY
    $BTU
    $COSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MARGENZA

    Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

    12/20/20 4:31:01 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $API
    $BBY
    $BTU
    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $API
    $BBY
    $BTU
    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Appia Announces Appointment of VP Corporate Development

    Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Appia Rare Earths & Uranium Corp. (CSE:API) (OTCQB:APAAF) (FSE: A0I0) (MUN: A0I0) (BER: A0I0) (the "Company" or "Appia") is pleased to announce that Jason Bagg has been appointed Vice-President Corporate Development, effective January 15, 2026. Mr. Bagg brings over 25 years of financial and uranium sector experience, including his position as Chief Executive Officer of Urano Energy Corp, and Puranium Energy Ltd. Tom Drivas, CEO of Appia, commented:"On behalf of the Board of Directors, it is my pleasure to welcome Jason to the Appia team. His experience in the financial markets and the uranium sector comes at a pivotal time as the Compa

    1/15/26 7:30:00 AM ET
    $API
    Computer Software: Prepackaged Software
    Technology

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $API
    $BBY
    $BTU
    $COSM
    Financials

    Live finance-specific insights

    View All

    Agora, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 2, 2026

    SANTA CLARA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ:API), a pioneer and leader in conversational AI and real-time engagement technology, will release its financial results for the fourth quarter and fiscal year ended December 31, 2025 after the close of U.S. markets on March 2, 2026. Agora, Inc. will host a conference call to discuss the financial results at 5 p.m. Pacific Time / 8 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 4Q 2025 Financial Results The call will be available at https://edge.media-server.com/mmc/p/9jcg52bqInvestors who want to hear the call should log on at least 15 minutes prior to t

    2/13/26 7:00:00 AM ET
    $API
    Computer Software: Prepackaged Software
    Technology

    Peabody Reports Results for the Quarter and Year Ended December 31, 2025

    Key Operational and Financial Metrics Meet or Exceed 2025 Full-Year Guidance Centurion Longwall Mining Ahead of Schedule U.S. Policy and Market Tailwinds Supportive of Increasing Coal Use ST. LOUIS, Feb. 5, 2026 /PRNewswire/ -- Peabody (NYSE:BTU) today reported fourth quarter net income attributable to common stockholders of $10.4 million, or $0.09 per diluted share, compared to $30.6 million, or $0.25 per diluted share, in the prior year quarter. Peabody had Adjusted EBITDA1 of $118.1 million in the fourth quarter of 2025, compared to $176.7 million in the fourth quarter of 2024. Full-year 2025 revenue totaled $3,861.5 million compared to $4,236.7 million in the prior year in the face of s

    2/5/26 7:46:00 AM ET
    $BTU
    Coal Mining
    Energy

    Peabody Board Declares Dividend on Common Stock

    ST. LOUIS, Feb. 5, 2026 /PRNewswire/ -- Peabody (NYSE:BTU) announced today that its Board of Directors has declared a quarterly dividend on its common stock of $0.075 per share, payable on March 10, 2026 to stockholders of record on February 23, 2026. Peabody is a leading coal producer, providing essential products for the production of affordable, reliable energy and steel. Our commitment to sustainability underpins everything we do and shapes our strategy for the future. For further information, visit PeabodyEnergy.com.  Contact:Vic Svec / Kala [email protected] Forward-Looking Statements This press release contains forward-looking statements within the meaning of the securities

    2/5/26 7:45:00 AM ET
    $BTU
    Coal Mining
    Energy

    $API
    $BBY
    $BTU
    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

    SC 13G/A - MACROGENICS INC (0001125345) (Subject)

    11/14/24 5:13:06 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care